Name: Baricitinib
Price: Inquiry

- Overview
  - Baricitinib is a Janus kinase inhibitor (JAK) currently used as monotherapy in the treatment of rheumatoid arthritis. Barictinib is also recommened for the treatment of atopic dermatitis and systemic lupus erythematosus. In mice interestingly, the administration of baricitinib reduced the inflammatory effects induced by a high-sugar diet on the metabolism.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Enzyme Modulators
    
    Alternative Name
    
    INCB 028050; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile; LY 3009104
    
    CAS Number
    
    1187594-09-7
    
    Molecular Formula
    
    C16H17N7O2S
    
    Molecular Weight
    
    371.42 g/mol
    
    MDL Number
    
    MFCD21608464
    
    Note
    
    There is no hazardous surcharge associated with this product.
    There is no special packaging charge associated with this product.
    
    * For research use only. Not for human or veterinary use
- Reference
  - Al-Salama et al (2018). Baricitinib: A Review in Rheumatoid Arthritis. Drugs 78:761–772.
    Collotta et al (2020) Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. Molecular Metabolism 39:101009.
    Markham (2017). Baricitinib: First Global Approval. Drugs 77:697–704.